Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies

4 Mar 2021

Abstract excerpt

Introduction: Alterations in DNA damage repair (DDR) genes are observed in up to 60% of biliary tract cancer (BTC) patients. Patients with advanced/metastatic BTC have few therapeutic options, so there is a demand for the development of new and innovative treatment approaches. The use of poly-adenosine diphosphate-ribose polymerase (PARP) inhibitors (PARPis), either as a monotherapy or in combination, is being...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33660569
DOI: 10.1080/13543784.2021.1898586

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studiesPMID 33660569Read ↗

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?Semantic proximity Read ↗

Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract CancerSemantic proximity Read ↗

Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision MedicineSemantic proximity Read ↗

Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal CancersSemantic proximity Read ↗

Targeting BRCA-mutant biliary tract cancer: Current evidence and future perspectives.Semantic proximity Read ↗

Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B.Semantic proximity Read ↗

Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving ParadigmSemantic proximity Read ↗

Emerging molecular target antagonists for the treatment of biliary tract cancer.Semantic proximity Read ↗

Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract CancerSemantic proximity Read ↗

New Treatment Options for Advanced Biliary Tract Cancer.Semantic proximity Read ↗

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applicationsSemantic proximity Read ↗

Rational development of combination therapies for biliary tract cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.